AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02620306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimsartan 60mg~120mg
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study NCT02620306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimsartan 60mg~120mg
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study NCT02620306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg~100mg
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study NCT02620306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg~100mg
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study NCT01145729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Feedback
Description: Providing providers biomarker feedback on childhood secondhand smoke exposure
Study NCT01145729 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Biomarker Feedback
Description: Providing providers biomarker feedback on childhood secondhand smoke exposure
Study NCT03794024 — intervention group
Intervention type: DEVICE
Intervention: The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
Description: The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study NCT03794024 — intervention group
Intervention type: DEVICE
Intervention: The Axium Neurostimulator System
Description: The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Systemic subcutaneous delivery of low-dose IL-2.
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus peptide melanoma vaccine
Study NCT00003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Study NCT04359511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
Study NCT02929186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-In Outreach
Description: Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
Study NCT02929186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-Out Outreach
Description: Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
Study NCT04122066 — intervention group
Intervention type: DRUG
Intervention: sofosbuvir \daclatsvir
Description: study the effect of the new oral antihepatitis C drugs on the respiratory system
Study NCT04327739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 Exercise
Description: • Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
Study NCT04327739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2 Exercise and INIT
Description: * Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique
Study NCT04327739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 3 Exercise and SMT
Description: * Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant.
Study NCT04327739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants allocated to this group received general consulting istructions and a home based general exercise sheet
Study NCT03898089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Core Stability Exercise
Description: The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
Study NCT03898089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise plus Myofascial Release Technique Group
Description: In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
Study NCT02865421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells
Description: adipose tissue derived stromal vascular fraction
Study NCT02865421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma transplanted in bald area at a distance
Study NCT01085734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25mg intravitreally
Study NCT01085734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osurdex
Description: 0.7mg intravitreally
Study NCT03201432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent (DES)
Description: Polymer-free paclitaxel eluting stents
Study NCT03201432 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bare metal stent (BES)
Description: Bare metal stent
Study NCT01229709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Tinnitus Reduction
Description: The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
Study NCT04810949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamine D3 supplementation
Description: 1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
Study NCT02378233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iodine
Description: The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
Study NCT02378233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are given a non-iodine containing multivitamin tablet
Study NCT02467127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
Study NCT03107052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab
Study NCT02263326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: 50 mg tablet by mouth once daily for 48 weeks
Study NCT02263326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: 300 mg tablet by mouth once daily for 48 weeks
Study NCT02263326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue current antiretroviral regimen
Description: Continue current DHHS recommended or alternative three-drug antiretroviral regimen
Study NCT04994028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
Study NCT04994028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment with volume Spirometry and deep breathing
Description: Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
Study NCT00841776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac
Description: Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
Study NCT00841776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziana gel
Description: Clindamycin and tretinoin gel once a day for 12 weeks.
Study NCT00141648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Description: Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
Study NCT00141648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total 45 Gy in 25 fractions
Study NCT04982341 — intervention group
Intervention type: PROCEDURE
Intervention: prone position
Description: patients are returned from prone to supine position while receiving oxygenation through HFNC
Study NCT02013778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Study NCT00933608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: participants will be asked to take memantine (20mg/day) for 16 weeks
Study NCT00933608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be asked to take 2 tablets per day to match active drug
Study NCT01388049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
Study NCT00769171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg every 24 h
Study NCT00769171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone + Metronidazole
Description: Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
Study NCT03608241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg by mouth (PO) Once daily (QD) for 11 days
Study NCT03608241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonogestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study NCT02371577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
Study NCT02482298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
Study NCT02482298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
Study NCT02681419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle fenestration
Description: This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
Study NCT02681419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture wick
Description: This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
Study NCT05130905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiteStart Supplement
Description: RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
Study NCT04401800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsules administered orally once daily
Study NCT04401800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study NCT02668705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: A computer generated character that can administer informed consent to a potential research subject.
Study NCT04408391 — intervention group
Intervention type: OTHER
Intervention: Brain MRI scan
Description: Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
Study NCT01643642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment/farmacotherapy intervention
Description: Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
Study NCT01643642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Other: Treatment As Usual
Study NCT01270932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexamethasone
Description: Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
Study NCT00880269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat/LBH589
Study NCT00352469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seroquel XR
Description: Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
Study NCT03337802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
Study NCT03050450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study NCT03050450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study NCT03050450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study NCT03050450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study NCT03050450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle